VLDL-C

There are 21 papers on VLDL-C in aging research: 3 trials and 7 observational studies in people, 2 in animals, 9 reviews.

Biomarker

21 papers study it29 more mention it2 findings

2 new papers in 30 daysSee all 50 papers on VLDL-C

“each 1 mmol/L increase in cumulative estimated VLDL-C was associated with higher CMM risk (HR = 1.210, P < 0.001)”
Sustained estimated VLDL-C exposure is associated with cardiometabolic multimorbidity and foam cell dysfunction: evidence from prospective cohorts and in vitro studiesJournal of geriatric cardiology : JGC2026doi:10.26599/1671-5411.2026.07.008
  • Human trial3
  • Humans7
  • Animals2

Interventions

1

Ashwagandha

downin humans1

1 study
  1. Ashwagandha decreases VLDL-C in humans (-76.50 mg/dL).

    Human trial40 daysn = 43

More on Ashwagandha

Associations

1

Cardiometabolic multimorbidity

upin humans1HR 1.21

1 study
  1. VLDL-C is linked with a higher risk of cardiometabolic multimorbidity in humans (CHARLS) (HR = 1.210).

    HumansCHARLS

More on Cardiometabolic multimorbidity

Latest

Dec 2025: 1Jan 2026: 4Feb 2026: 3Mar 2026: 4Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 1Aug 2026: 1Sep 2026: 2Oct 2026: 2Nov 2026: 019 papers in 12 months

See all 50 papers on VLDL-C